Diagnosis of Opioid Use Disorder by Youths Assessed in Acute Care Settings in British Columbia, Canada

Author(s):  
Emanuel Krebs ◽  
Charlie Zhou ◽  
Jeong E. Min ◽  
Connie Carter ◽  
Gina McGowan ◽  
...  
2020 ◽  
Vol 29 (17-18) ◽  
pp. 3122-3135
Author(s):  
Christine A. Fournier Bell ◽  
Mary McCurry

2021 ◽  
Vol 130 ◽  
pp. 108404
Author(s):  
Emanuel Krebs ◽  
Jeong E. Min ◽  
Haoxuan Zhou ◽  
Carolyn Davison ◽  
Gina McGowan ◽  
...  

2019 ◽  
Vol 13 (5) ◽  
pp. 408-411 ◽  
Author(s):  
Patrick Hemmons ◽  
Paxton Bach ◽  
Kate Colizza ◽  
Seonaid Nolan

Addiction ◽  
2021 ◽  
Author(s):  
Benjamin Enns ◽  
Emanuel Krebs ◽  
Trevor Thomson ◽  
Laura M. Dale ◽  
Jeong Eun Min ◽  
...  

Addiction ◽  
2020 ◽  
Vol 115 (8) ◽  
pp. 1482-1493 ◽  
Author(s):  
Micah Piske ◽  
Haoxuan Zhou ◽  
Jeong E. Min ◽  
Natt Hongdilokkul ◽  
Lindsay A. Pearce ◽  
...  

2020 ◽  
Author(s):  
◽  
Mary MacLellan

Stigma is a complex phenomenon with a myriad of detrimental health and social impacts that are not fully studied or understood. Persistent stigma exists towards individuals who have opioid use disorder (OUD) in British Columbia. OUD is a chronic, relapsing, clinical condition that has been identified as one of the most challenging substance use disorders. For those affected, they must also endure the consequences of stigma that promote barriers to health care, health and social inequalities, diminished quality of life as well as increased morbidity and mortality. The current unremitting opioid overdose crisis in British Columbia further emphasizes the importance of eradicating stigma towards individuals who use opioids and/or suffer from OUD, as untreated OUD is fueling this multifaceted public health emergency. For these reasons, an integrative literature review has been conducted to identify how primary care providers in British Columbia can address the intersecting stigmas for individuals suffering OUD. The results are discussed within the context of primary health care in British Columbia. Whittemore and Knafl’s approach to the integrative literature review was utilized in this study to review eleven pertinent articles. The findings suggest that stigma occurs on varying levels for individuals with OUD that serve to reinforce each other and manifest as discrimination, mistrust, social distancing, minimized advocacy, unequal access to health care and suboptimal health care. Further, the findings indicated that the role of primary care providers may be instrumental in eradicating stigma in a timely manner. Recommendations for primary care providers to dismantle the stigma associated with OUD are discussed, and specific strategies for the primary care setting are presented.


BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e036102
Author(s):  
Micah Piske ◽  
Trevor Thomson ◽  
Emanuel Krebs ◽  
Natt Hongdilokkul ◽  
Julie Bruneau ◽  
...  

IntroductionDespite a recent meta-analysis including 31 randomised controlled trials comparing methadone and buprenorphine for the treatment of opioid use disorder, important knowledge gaps remain regarding the long-term effectiveness of different treatment modalities across individuals, including rigorously collected data on retention rates and other treatment outcomes. Evidence from real-world data represents a valuable opportunity to improve personalised treatment and patient-centred guidelines for vulnerable populations and inform strategies to reduce opioid-related mortality. Our objective is to determine the comparative effectiveness of methadone versus buprenorphine/naloxone, both overall and within key populations, in a setting where both medications are simultaneously available in office-based practices and specialised clinics.Methods and analysisWe propose a retrospective cohort study of all adults living in British Columbia receiving opioid agonist treatment (OAT) with methadone or buprenorphine/naloxone between 1 January 2008 and 30 September 2018. The study will draw on seven linked population-level administrative databases. The primary outcomes include retention in OAT and all-cause mortality. We will determine the effectiveness of buprenorphine/naloxone vs methadone using intention-to-treat and per-protocol analyses—the former emulating flexible-dose trials and the latter focusing on the comparison of the two medication regimens offered at the optimal dose. Sensitivity analyses will be used to assess the robustness of results to heterogeneity in the patient population and threats to internal validity.Ethics and disseminationThe protocol, cohort creation and analysis plan have been approved and classified as a quality improvement initiative exempt from ethical review (Providence Health Care Research Institute and the Simon Fraser University Office of Research Ethics). Dissemination is planned via conferences and publications, and through direct engagement and collaboration with entities that issue clinical guidelines, such as professional medical societies and public health organisations.


Sign in / Sign up

Export Citation Format

Share Document